This inventor holds 1 USPTO granted patent. Top assignee: Je Il Pharmaceutical Co., Ltd.. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Han-Chang Lee: Innovator in Pharmaceutical Chemistry
Introduction
Han-Chang Lee is a notable inventor based in Yongin-si, South Korea. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel compounds with therapeutic potential.
Latest Patents
Han-Chang Lee holds a patent for a tricyclic derivative or pharmaceutically acceptable salts thereof, along with its preparation method and pharmaceutical composition. This invention relates to a novel tricyclic derivative that exhibits efficient inhibitory activity against poly(ADP-ribose) polymerases (PARP). The tricyclic derivative is particularly useful for the prevention or treatment of diseases caused by excess PARP activity, including neuropathic pain, neurodegenerative diseases, cardiovascular diseases, diabetic nephropathy, inflammatory diseases, osteoporosis, and cancer.
Career Highlights
Han-Chang Lee is associated with Je Il Pharmaceutical Co., Ltd., where he continues to advance his research and development efforts. His work focuses on creating innovative solutions to address various health challenges.
Collaborations
He has collaborated with notable colleagues, including Myung-Hwa Kim and Seung-Hyun Kim, to further enhance the impact of his research in the pharmaceutical industry.
Conclusion
Han-Chang Lee's contributions to pharmaceutical chemistry through his innovative patent demonstrate his commitment to improving healthcare solutions. His work has the potential to significantly impact the treatment of various diseases.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile